Sutro Biopharma announced the appointment of Barbara Leyman, Ph.D., as Chief Business Development Officer, effective July 8, 2024. Dr. Leyman brings 20 years of life science industry business development, investing, and corporate strategy experience to Sutro. Dr. Leyman most recently served as Senior Vice President of Corporate Development at GenEdit
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STRO:
- Sutro Biopharma management to meet with JMP Securities
- Coping with a Wild Ride: Investing in Sutro Biopharma (NASDAQ:STRO)
- Biotech Alert: Searches spiking for these stocks today
- Bank of America Predicts up to ~200% Surge for These 2 ‘Strong Buy’ Stocks
- Sutro Biopharma reports Q1 EPS (95c), consensus (92c)